Tag: EU HTA regulation
-
EU JCA Evidence Requirements: Lessons for Pharma in 2026
EU JCA Is Now Operational: What the First Assessments Reveal About Evidence, RWE and Market Access The European Union’s Joint Clinical Assessment framework has moved decisively from policy into practice. Since the EU Health Technology Assessment Regulation became applicable in January 2025, pharmaceutical and biotechnology companies have been preparing for new timelines, evidence requirements and…
-
EU HTA Joint Clinical Assessments: 7 Critical Pharma Mistakes
EU HTA Joint Clinical Assessments (JCA): The 7 Critical Mistakes Pharma Companies Must Avoid Before Their First Submission The European healthcare landscape is undergoing one of the most significant transformations in decades. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation and the introduction of Joint Clinical Assessments (JCA), pharmaceutical and…
-
DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE
Mastering DARWIN EU 2.0 Interoperability for JCA Compliance: The Technical Blueprint for Multi-State Real-World Evidence The European market access landscape is undergoing its most profound structural disruption since the centralization of regulatory approvals. The rollout of the European Union Health Technology Assessment (EU-HTA) regulation has effectively shifted the goalposts for pharmaceutical manufacturers. No longer can…
-
Drug Value with RWE and Role of AI in EU’s JCA
Drug Value with Real-World Evidence (RWE): Opportunities, Challenges, and the Role of AI in EU’s Joint Clinical Assessment (JCA) What is Real-World Evidence and Why It Matters in the EU HTA Landscape Real-World Evidence (RWE) refers to health data gathered outside of traditional clinical trials. It comes from sources like electronic health records, patient registries,…
-
Pharma Market Access 2025: HTA, U.S. Drug Pricing, and Tariffs
Global Pharma Market Access Under Pressure Pharma market access is no longer just a regulatory hurdle, it’s a geopolitical challenge. With the EU’s new HTA regulation, U.S. pricing reforms, potential Trump tariffs, and legislative shifts in key markets, pharmaceutical access is facing cross-border disruption. Manufacturers must realign their strategies to sustain revenue and reach patients.…